Our results suggested that the combination of VEGF-Trap and gemcitabine might be a more effective alternative for human lung cancer, which may form the basis of a rationale for human clinical studies to investigate the benefits of the combination therapy of VEGF-Trap and gemicitabine in lung cancer. This evidence concerns the gene VEGFA and lung carcinoma.